US pharma groups advance $25 bn opioid settlement
-
Turkish Energy Minister Highlights Qatar as Key Partner for Regional and Global Energy Security
-
Rene Eyre Revisits Autobiographical Performance 'Say A Little Prayer' in London
-
London Museum Granted 24/7 License Ahead of November Opening
-
UAE's HCT Holds Record Graduation and Announces Major Training Expansion
-
Dana White Confirms Flight to Washington for Trump Meeting on Press Secretary Role
-
NASA Awards $10B Lunar Contract Framework to SpaceX, Blue Origin
-
Dengue Fever Expands Into High Himalayas as Climate Change Warms Nepal
-
Katy Perry Tells Fans Ex-Husband Russell Brand 'Should Be in Jail' During UK Concert
-
IoT Refrigerator Hacks Disrupt Blood Labs and Supermarkets Across Europe and US
-
South African election results renew debate over identity-based voting
-
Post-election pressures complicate US and Israeli decisions on Iran
-
South African voters report smoother local election but declining IEC trust
-
UN members approve talks on treaty protocol against environmental crime
-
Dolly Parton museum and Nashville hotel open after singer’s death
-
Family-run West Sussex beach café prepares for first winter season
-
George and Amal Clooney attend New York political-comedy reading
-
CT scans reveal health and burial clues from Egypt’s Braided Lady mummy
-
British buyers pay substantial premiums for period-home appearance
-
Oxford faces complaints over lecturer’s classroom attire
-
Thomas Markle released to house arrest after child-abuse-image charge
-
Kyren Wilson and John Higgins reach International Championship snooker final
US pharma groups advance $25 bn opioid settlement
Johnson & Johnson and three large drug distributors said Friday that opioid settlements worth nearly $25 billion had garnered enough support from opposing litigants to be finalized in court.
The three distributors, McKessen, AmerisourceBergen and Cardinal Health, each "independently determined" that enough states and litigating political subdivisions had signed on to advance the agreement to pay out $19.5 billion over 18 years to thousands of plaintiffs, according to a joint press release from the companies.
The statement noted that "the companies continue to strongly dispute the allegations made against them", but called the agreement "a key milestone toward achieving broad resolution of governmental opioid claims and delivering meaningful relief to communities across the United States that have been impacted by the opioid epidemic."
The sum is slightly smaller than the amount given in July 2021 when the agreement was first announced. The difference reflects the participation level in the deal, which involved more than 90 percent of states and jurisdictions that sued.
The final step in the process will be for both sides to seek a court order finalizing the agreement. The first annual payment could begin as soon as April 2, 2022, the companies said.
Johnson & Johnson released a similar statement regarding participation in its agreement to pay $5 billion to address nationwide claims, adding that the agreement "is not an admission of any liability or wrongdoing."
The US opioid crisis has claimed more than 500,000 lives over the last 20 years and ensnared some of the largest firms in the world of American medicine.
The same four companies reached an agreement to pay $590 million to settle lawsuits connected to opioid addiction among Native American tribe members, according to a US court filing earlier this month.
A.Silveira--PC
